Bristol Myers Squibb's Neuroscience Renaissance Driven by Strategic Acquisitions and Pipeline Expansion

Bristol Myers Squibb Re-enters Neuroscience with Robust Pipeline

Bristol Myers Squibb is strategically re-establishing its presence in neuroscience, a therapeutic area it exited in 2013. This 'renaissance' began with the $74 billion acquisition of Celgene in 2019, which brought foundational assets like Zeposia (ozanimod) for multiple sclerosis. The company is now building a robust pipeline, including Cobenfy for schizophrenia and Alzheimer's disease psychosis, irafamdastat for MS spasticity and Alzheimer's agitation, and moponetug for Alzheimer's. BMS emphasizes a 'continuum of care' strategy, developing both disease-modifying therapies and symptomatic treatments, and is investing in brain shuttle technologies to enhance drug delivery across the blood-brain barrier.

• Bristol Myers Squibb's renewed focus on neuroscience, a field it previously exited in 2013, was significantly catalyzed by its $74 billion mega-merger with Celgene in 2019. This acquisition provided a foundational portfolio, including the S1P receptor modulator Zeposia (ozanimod) approved in March 2020 for multiple sclerosis, enabling BMS to rebuild its neuroimmunology and neuroinflammation drug development capabilities.
• The company's expanding neuroscience pipeline includes several promising assets. Cobenfy, acquired through the $14 billion Karuna Therapeutics purchase, is being evaluated for schizophrenia and Alzheimer’s disease psychosis, with readouts expected in 2027. Other assets include irafamdastat, a dual FAAH/MAGL inhibitor in Phase 2 for MS spasticity and Alzheimer’s agitation, and the anti-MTBR-tau antibody moponetug, also in Phase 2 for Alzheimer’s.
• BMS is pursuing a 'continuum of care' strategy in Alzheimer's disease and other areas, aiming to develop both disease-modifying therapies and treatments for debilitating symptoms. A key innovation focus is brain shuttle technologies, exemplified by a global license agreement with BioArctic for its BrainTransporter technology. This aims to improve drug delivery across the blood-brain barrier, potentially enabling more convenient administration and targeting previously undruggable mechanisms.

Navigating the Evolving Alzheimer's Disease Treatment Landscape

The treatment landscape for Alzheimer's disease has undergone a fundamental transformation over the past five years, most notably through the emergence of disease-modifying therapies targeting amyloid-β pathology. While acetylcholinesterase inhibitors (AChEIs) have long represented the standard of care, published trial data confirm they were not associated with slower progression of cognitive decline on CDR-SOB or ADAS-Cog relative to placebo. In contrast, anti-amyloid monoclonal antibodies (mABs) have demonstrated statistically significant attenuation of clinical worsening. A pooled analysis of seven mAB trials (n=8,010; mean age 71.5 years) versus nine AChEI trials (n=4,993; mean age 70.7 years) showed that mABs were associated with slower progression on CDR-SOB (mean difference −0.41, 95% CrI −0.61 to −0.22) and ADAS-Cog (−1.35, −2.36 to −0.36) compared to placebo, and outperformed AChEIs on CDR-SOB (−0.30, −0.60 to −0.001). Lecanemab received full FDA approval and regulatory endorsement from four agencies through varying pathways, marking a watershed moment in AD therapeutics. Donanemab received US approval with European decisions pending. Among individual agents, lecanemab demonstrated a 27% reduction in cognitive decline on ADCOMS and achieved amyloid-negative PET scans in 81% of participants in the Clarity AD trial, while donanemab achieved 76% plaque clearance and a 35% slowing of decline in early AD populations.

Notwithstanding these advances, the clinical meaningfulness of mAB benefit remains a subject of active scrutiny. Across both CDR-SOB and ADAS-Cog, observed effects did not reach the established minimally important difference thresholds (−1 and −2, respectively), indicating that antibody effects remained below the threshold of clinically meaningful change within the studied timeframes. However, given that these agents demonstrably interfere with underlying AD pathophysiology — including large-effect-size reductions in amyloid PET burden — cumulative benefit over longer treatment horizons remains a plausible and consequential consideration. Safety has emerged as an equally defining dimension of this landscape. Amyloid-related imaging abnormalities (ARIA), encompassing vasogenic edema (ARIA-E) and microhemorrhages/siderosis (ARIA-H), represent the most clinically significant adverse event class. APOE ε4 homozygotes carry a 5.53-fold increased odds of ARIA-E (95% CrI 2.48–13.07) relative to non-carriers. Analysis of the FAERS database identified 1,286 reports comprising 2,627 adverse events, of which 30% were classified as serious, including 46 deaths. Current guidelines now mandate APOE genotyping and risk-adapted MRI monitoring protocols — including FLAIR and susceptibility-weighted imaging — prior to and throughout therapy, with all regulatory authorities requiring post-marketing surveillance programs.

Looking beyond amyloid, the therapeutic pipeline reflects a deeper mechanistic understanding of Alzheimer's disease as a system-wide disorder involving neuroinflammatory and immunological cascades that facilitate pathological protein aggregation and neurodegeneration. Tau-targeting strategies have advanced meaningfully into clinical development, encompassing four mechanistic subgroups: tau phosphorylation inhibitors, microtubule stabilizers, tau clearance enhancers, and tau aggregation inhibitors, with passive immunotherapy representing the predominant approach under investigation. Concurrently, both innate and adaptive immune responses are increasingly recognized as substantive contributors to the pathological cascade and clinical heterogeneity of AD, opening additional avenues for therapeutic intervention. Together, these developments signal a maturing pipeline that is moving progressively toward mechanism-driven, biomarker-stratified treatment paradigms.

Pioneering Novel Targets and Brain Shuttle Technologies in AD

Neuroinflammatory pathways have emerged as a central focus of next-generation Alzheimer's disease (AD) therapeutics. CD33 and TREM2 — two microglial receptors that modulate neuroinflammatory signaling — have advanced from target identification to active clinical investigation. Strategies to inhibit CD33 span gene therapy, small molecules, and immunotherapy, while TREM2 activity is being enhanced via monoclonal antibody approaches. Notably, AL002 (anti-TREM2) and AL003 (anti-CD33) are both progressing through large-scale clinical trials as putative disease-modifying agents. Concurrently, inflammasome pathways — including NF-κB, NLRP3, TREM2-associated signaling, and the cGAS-STING axis — are being characterized both as biomarkers of AD-associated neuroinflammation and as tractable drug targets, with several compounds from this mechanistic class also entering clinical evaluation.

Metabolic and lipid-related targets represent another emerging frontier. ABCA7 loss-of-function has been linked to dysregulated phosphatidylcholine synthesis, triglyceride accumulation, mitochondrial dysfunction, and elevated intracellular amyloid-β42 — a convergence of pathological features that positions this pathway as therapeutically compelling. CDP-choline supplementation has demonstrated the capacity to reverse these abnormalities in ABCA7 loss-of-function induced neurons, normalizing amyloid-β secretion and neuronal hyperexcitability. GLP-1 receptor agonists have also attracted significant interest as neuroprotective agents; exenatide (100 µg/kg twice daily for 16 weeks) prevented cognitive decline and reduced Aβ deposition and synaptic damage in the 5xFAD transgenic model, while liraglutide (300 µg/kg daily subcutaneously for 6 weeks) improved learning and memory and reduced hippocampal neuronal death in streptozotocin-treated animals.

PPAR-gamma activation represents an additional mechanistic avenue under exploration, with relevance extending across neurodegenerative conditions. Activation of this nuclear receptor has been associated with improvements in insulin sensitivity, modulation of dopaminergic signaling, inhibition of neuroinflammation, and favorable effects on mitochondrial bioenergetics and oxidative stress — a broad mechanistic profile that aligns well with the multifactorial pathophysiology of AD. Collectively, these emerging targets reflect a strategic shift in the field toward addressing neuroinflammation, metabolic dysregulation, and mitochondrial dysfunction as core disease drivers, complementing the more established amyloid and tau-centric therapeutic paradigms.

BMS's Bold Neuroscience Re-Entry: A Continuum of Innovation

Bristol Myers Squibb's ambitious return to neuroscience signals a strategic pivot designed to re-establish its footprint in a therapeutic area characterized by high unmet need and significant scientific challenges. This move is not merely a re-entry but a calculated expansion, building upon the foundation of established assets like Zeposia for multiple sclerosis, which has demonstrated sustained efficacy and cognitive benefits. The company's pipeline reflects a dual focus: addressing symptomatic relief with agents like Cobenfy for schizophrenia and Alzheimer's disease psychosis, and pursuing disease modification with therapies targeting Alzheimer's pathology, such as moponetug and irafamdastat.

Cobenfy, with its novel muscarinic receptor agonist mechanism, represents a particularly intriguing development. Unlike current antipsychotics that primarily block dopamine receptors, Cobenfy offers a differentiated approach that has shown significant reductions in both positive and negative symptoms of schizophrenia in clinical trials. This could position it as a valuable new option, especially given its favorable profile regarding extrapyramidal symptoms and weight gain, which are common with traditional antipsychotics. However, clinicians will need to manage its associated cholinergic and anticholinergic adverse events, such as gastrointestinal issues.

Beyond specific drug candidates, BMS is investing in cutting-edge platforms like brain shuttle technologies. This is a critical strategic move, as the blood-brain barrier remains a formidable obstacle for many promising neurotherapeutics, particularly biologics. By enhancing the delivery of antibodies and other large molecules to the brain, these technologies could unlock new therapeutic avenues for conditions like Alzheimer's disease, where effective target engagement has been historically difficult. While preclinical evidence for such shuttles is compelling, translating this into consistent and safe clinical success for complex brain disorders, especially given the high failure rate in Alzheimer's drug development, will be a significant undertaking. This integrated strategy, combining proven assets, novel mechanisms, and advanced delivery platforms, positions BMS to potentially become a major player in the evolving neuroscience landscape.